The operating EBITDA (Earnings Before Interest Depreciation and Taxes) improved by 24 per cent to Rs 251 crore, and profit after taxes showed strong growth of 36 per cent to Rs151 crore compared to Rs 111 crore in Q2 FY23
Read More
In the second quarter of the fiscal year 2024, Zydus Lifesciences reported a significant 9 per cent year-over-year increase in revenue from operations, reaching Rs. 43,688 million
Read More
This growth was driven by an increase in the average revenue per occupied bed (ARPOB) across all hospitals, resulting in an impressive 13 per cent year-on-year expansion
Read More
India's public healthcare expenditure has seen a notable increase, reaching 2.1 per cent and 2.2 per cent of the gross domestic product (GDP) in FY23 and FY22, compared to 1.6 per cent in FY21
Read More
A total of 5,600,000 newly issued equity shares, each with a face value of Rs. 10 per share, are included in this offering. Corporate Capital Ventures has been appointed as the Book Running Lead Manager overseeing the issue, while KFIN Technologies Limited takes on the role of Registrar.
Read More
The company reported Earnings before Interest, Depreciation and Tax (EBIDTA) at Rs. 16.8 crores and Net profit for the quarter at Rs. 59 crores
Read More
IMPCL is a significant supplier to dispensaries and clinics operating under the Central Government Health Scheme
Read More
The company previously held the Two Star Export House status, which required export performance criteria of USD 25 million
Read More
